Kathy Coleman commits additional $3.5 million to fuel the future of clinical trials at University Hospitals Seidman Cancer Center
Grant and Award Announcement
Updates every hour. Last Updated: 4-Sep-2025 17:11 ET (4-Sep-2025 21:11 GMT/UTC)
A $3.5 million gift from Kathy Coleman to Because of You: The Campaign for University Hospitals will fuel the future of clinical trials at University Hospitals Seidman Cancer Center. The critical support will allow for site renovations and expansion – in size and scale - of the existing Kathy and Les Coleman Clinical Trials Center.
A new peer-reviewed study from the Environmental Working Group finds that advanced PFAS filtration systems not only remove toxic "forever chemicals" from drinking water but also significantly reduce other harmful contaminants. These include cancer-linked disinfection byproducts, agricultural nitrates, and heavy metals like arsenic and uranium. The study, published in ACS ES&T Water, analyzed data from 19 U.S. utilities and the EPA’s national monitoring program, showing that technologies like granular activated carbon, ion exchange, and reverse osmosis offer broader public health benefits than previously recognized.
When detached cancer cells squeeze through the tiniest blood vessels they can become prone to grow new tumours far from where they started, a blood flow simulation experiment suggests.
Researchers from the Department of Clinical Oncology, Centre of Cancer Medicine, School of Clinical Medicine, LKS Faculty of Medicine of the University of Hong Kong (HKUMed), have discovered that the Epstein-Barr virus (EBV), a common human virus closely linked to nasopharyngeal carcinoma (NPC), can change the 3D structure of the human genome inside cancer cells, much like assembling building blocks. This groundbreaking finding reveals the mechanism by which EBV actively promotes cancer progression and offers promising avenues for developing targeted therapies for patients, with the aim of saving more lives. The findings were published in the scientific journal Nature Communications.
New research shows that colorectal cancer is unique in having its own microbial ‘fingerprint’. Colorectal cancer is the fourth most common cancer in the UK and the second deadliest. The research could help doctors better understand how this cancer develops, how aggressive it might be, and even how a patient might respond to treatment. The team studied whole genome sequencing (WGS) data from more than 9,000 cancer patients. The analysis also challenges scientific claims that all cancers are associated with a unique microbial fingerprint